Fudan University, established in 1905, is a multi-disciplinary comprehensive research university in liberal arts, science, and medicine. It has been honourably selected into the 985 Project and University-Based Institutes for Advanced Study (UBIAS), which currently ranks 31st in the QS comprehensive academic ranking in 2022.

Founded in 1926, the Department of Chemistry at Fudan University is one of the four core members of the 2011-Collaborative Innovation Center of Chemistry for Energy Materials (2011-iChEM). It hosts the Shanghai Key Laboratory of Molecular Catalysis and Innovative Materials, Shanghai Key Laboratory of Chemical Biology for Protein Research, Engineering Research Center of Innovative Scientific Instrument of MOE, and Shanghai Engineering Research Center of Industrial Asymmetric Catalysis of Chiral Drugs.

The Department of Chemistry has five secondary disciplines of chemistry including inorganic chemistry, analytical chemistry, organic chemistry, physical chemistry, and chemical biology, focusing on green chemistry and interdisciplinary chemistry with actively high-tech and application-oriented development. More than 100 papers were published in high-level journals such as Science, Nature, and their sub-journals, as well as J. Am. Chem. Soc., Angew. Chem. Int. Ed. and other top chemistry journals. In 2020-2021, the Chemistry major was ranked 25th in QS and ranked 31st in the US News.

The Department of Chemistry has diverse research fields, including 1) comprehensive utilization of novel nanostructured materials for photocatalysis, biomedicine, and water treatment; 2) integrated utilization of atom-economic reactions of unsaturated hydrocarbons such as allenes and alkynes; 3) total synthesis of natural products; 4) discovery and development of non-nucleoside reverse transcriptase inhibitors for HIV therapy.

The Department of Chemistry has also developed a series of core technologies in the fields of chiral drug and chiral technology, nonconventional green process, and a large multi-scale computational modeling platform. In particular, the core technology platform for industrial asymmetric catalysis of chiral drugs has been built and improved, realizing an R&D platform and a pilot-scale platform capable of conducting basic research-technology development-industrial simulation-achievement industrialization in an entire-process, open manner. In the meantime, core asymmetric catalysis technologies are mainly applied to the development of chiral active pharmaceutical ingredients (APIs) for the treatment of major infectious diseases, cardiovascular and cerebrovascular diseases, as well as malignant tumors.

For detailed information please visit https://www.fudan.edu.cn/en
Copyright © 2020 Engineering Center of Catalysis and Synthesis for Chiral molecules, Fudan University. Production and hosting by Elsevier on behalf of KeAi Communications Co. Ltd.